DocWire News Editors

DocwireNews

According to a poster presentation at the 2021 American Society of Hematology, prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community. The findings were shared by Bruce E. Christensen, DSc, PA-C, of UT Health San Antonio and Mays Cancer Center. Dr. Christensen and colleagues presented the results of a survey focused on the scope of practice of APPs in oncology.The survey was sent in January 2021 to 1,307 members of the Association of Physician Assistants in Oncology (APAO). The response rate was 11%. Of the respondents, 95% were physician assistants (PAs), 3% were nurse practitioners (NPs), and 1% were described as &ldquo;other.&rdquo; Most respondents (87%) worked in medical oncology, but some worked in surgical oncology (6%) or radiation oncology (1%).A total of 44% of respondents reported that they were able to independently sign chemotherapy orders, while 56% did not independently sign chemotherapy orders.Of those who could sign orders, 60% worked in academic oncology centers and 35% worked in community oncology centers. In addition, 23% were only allowed to sign existing chemotherapy plans that did not require modifications.Only 35% of respondents could initiate and sign new chemotherapy orders. Instead, the majority (89%) could sign existing orders. Most respondents were able to prescribe intravenous and oral medications, but only about one-third could prescribe intrathecal medications, and about half could prescribe clinical trial medications.Of those respondents who could not prescribe chemotherapy, 74% worked in academic centers and 19% worked in a community practice. Most respondents reported no restrictions from the state medical board that would prohibit them from prescribing chemotherapy. However, 69% reported that their institution or facility did prohibit them from prescribing chemotherapy.The survey also explored physician and employer attitudes towards APPs prescribing chemotherapy. Respondents were asked if their physician colleagues believed that limiting chemotherapy to physicians is a safety measure. About one-third reported that this was true, about one-third that this was false, and about one-third unsure.APPs were also asked if they thought their physician colleagues believed experienced APPs should be allowed to prescribe chemotherapy. Again, the researchers reported mixed responses: 44% agreed, 11% disagreed, and 44% were unsure.Finally, the APPs were asked if their employer believed experienced APPs should be allowed to prescribe chemotherapy. Here, 30% reported this statement as true, 20% said it was false, and about half said they were unsure.

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

Oncology Advanced Practice Providers Face Constraints on Prescribing Authority

ASH Annual Meeting and Exposition 2021

According to a poster presentation at the 2021 American Society of Hematology, prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe